FDA Advisory Committee rejects nebivolol + valsartan combination for Hypertension- Forest/Actavis

Actavis plc has confirmed that the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to recommend against approval of Actavis' New Drug Application (NDA) for the fixed-dose combination of nebivolol and valsartan for the treatment of Hypertension. The committee vote was six to four recommending against approval.